{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:34:16Z","timestamp":1770507256863,"version":"3.49.0"},"reference-count":44,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":711,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1002\/jcph.170","type":"journal-article","created":{"date-parts":[[2013,8,28]],"date-time":"2013-08-28T12:46:39Z","timestamp":1377693999000},"page":"225-233","source":"Crossref","is-referenced-by-count":16,"title":["Estimation and comparison of carbamazepine population pharmacokinetics using dried blood spot and plasma concentrations from people with epilepsy: The clinical implication"],"prefix":"10.1002","volume":"54","author":[{"given":"Sing Teang","family":"Kong","sequence":"first","affiliation":[{"name":"National University of Singapore; Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Hui","family":"Lim","sequence":"additional","affiliation":[{"name":"Singapore General Hospital; Singapore Singapore"},{"name":"National Neuroscience Institute; Singapore Singapore"},{"name":"Duke-National University of Singapore; Graduate Medical School; Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Chan","sequence":"additional","affiliation":[{"name":"National University of Singapore; Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul C.","family":"Ho","sequence":"additional","affiliation":[{"name":"National University of Singapore; Singapore Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,20]]},"reference":[{"key":"10.1002\/jcph.170-BIB0001|jcph170-cit-0001","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2165\/00002018-199309030-00003","article-title":"Antiepileptic drugs. A review of clinically significant drug interactions","volume":"9","author":"Patsalos","year":"1993","journal-title":"Drug Saf."},{"key":"10.1002\/jcph.170-BIB0002|jcph170-cit-0002","first-page":"306","article-title":"Principles of clinically important drug interactions with carbamazepine. Part II","volume":"11","author":"Ketter","year":"1991","journal-title":"J Clin Psychopharmacol."},{"key":"10.1002\/jcph.170-BIB0003|jcph170-cit-0003","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00191168","article-title":"Early stage autoinduction of carbamazepine metabolism in humans","volume":"47","author":"Bernus","year":"1994","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1002\/jcph.170-BIB0004|jcph170-cit-0004","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00007691-199410000-00005","article-title":"Influence of sex, age, weight, and carbamazepine dose on serum concentrations, concentration ratios, and level\/dose ratios of carbamazepine and its metabolites","volume":"16","author":"Liu","year":"1994","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0005|jcph170-cit-0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007691-199404000-00004","article-title":"Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy","volume":"16","author":"Liu","year":"1994","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0006|jcph170-cit-0006","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1176\/ajp.134.3.304","article-title":"Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine","volume":"134","author":"Garver","year":"1977","journal-title":"Am J Psychiatry."},{"key":"10.1002\/jcph.170-BIB0007|jcph170-cit-0007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archpsyc.1980.01780160071008","article-title":"Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia","volume":"37","author":"Casper","year":"1980","journal-title":"Arch Gen Psychiatry."},{"key":"10.1002\/jcph.170-BIB0008|jcph170-cit-0008","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/BF00174361","article-title":"Concentrations of thioridazine and thioridazine metabolites in erythrocytes","volume":"89","author":"Svensson","year":"1986","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1002\/jcph.170-BIB0009|jcph170-cit-0009","first-page":"194","article-title":"Cost of antiepileptic drug monotherapies and combination therapies at a tertiary referral hospital in Singapore","volume":"53","author":"Lim","year":"2012","journal-title":"Epilepsia."},{"key":"10.1002\/jcph.170-BIB0010|jcph170-cit-0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00003088-198917030-00006","article-title":"Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication","volume":"17","author":"Summers","year":"1989","journal-title":"Clin Pharmacokinet."},{"key":"10.1002\/jcph.170-BIB0011|jcph170-cit-0011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/j.1875-9114.1998.tb03853.x","article-title":"Population pharmacokinetics of carbamazepine in adults with epilepsy","volume":"18","author":"Graves","year":"1998","journal-title":"Pharmacotherapy."},{"key":"10.1002\/jcph.170-BIB0012|jcph170-cit-0012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2710.2006.00717.x","article-title":"Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage","volume":"31","author":"Bondareva","year":"2006","journal-title":"J Clin Pharm Ther."},{"key":"10.1002\/jcph.170-BIB0013|jcph170-cit-0013","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jcph.8","article-title":"Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy","volume":"53","author":"Ahmed","year":"2013","journal-title":"J Clin Pharmacol."},{"key":"10.1002\/jcph.170-BIB0014|jcph170-cit-0014","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":"Population pharmacokinetics of carbamazepine in Chinese epilepsy patients","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0015|jcph170-cit-0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.0306-5251.2001.01396.x","article-title":"Population pharmacokinetics of carbamazepine in Singapore epileptic patients","volume":"51","author":"Chan","year":"2001","journal-title":"Br J Clin Pharmacol."},{"key":"10.1002\/jcph.170-BIB0016|jcph170-cit-0016","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia."},{"key":"10.1002\/jcph.170-BIB0017|jcph170-cit-0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-198611030-00001","article-title":"Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update","volume":"11","author":"Bertilsson","year":"1986","journal-title":"Clin Pharmacokinet."},{"key":"10.1002\/jcph.170-BIB0018|jcph170-cit-0018","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s002280050475","article-title":"A model for the determination of carbamazepine clearance in children on mono- and polytherapy","volume":"54","author":"Gray","year":"1998","journal-title":"Eur J Clin Pharmacol."},{"key":"10.1002\/jcph.170-BIB0019|jcph170-cit-0019","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/BF03261932","article-title":"Fundamentals of population pharmacokinetic modelling: validation methods","volume":"51","author":"Sherwin","year":"2012","journal-title":"Clin Pharmacokinet."},{"key":"10.1002\/jcph.170-BIB0020|jcph170-cit-0020","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/FTD.0b013e31815c15f3","article-title":"Population pharmacokinetic model of carbamazepine derived from routine therapeutic drug monitoring data","volume":"29","author":"Vucicevic","year":"2007","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0021|jcph170-cit-0021","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/j.1552-4604.1996.tb04246.x","article-title":"Detection of carbamazepine drug interaction by multiple peak approach screening using routine clinical pharmacokinetic data","volume":"36","author":"Yukawa","year":"1996","journal-title":"J Clin Pharmacol."},{"key":"10.1002\/jcph.170-BIB0022|jcph170-cit-0022","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00007691-198002040-00003","article-title":"Carbamazepine plasma levels in children and adults: influence of age, dose, and associated therapy","volume":"2","author":"Battino","year":"1980","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0023|jcph170-cit-0023","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/00007691-198709000-00008","article-title":"Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication","volume":"9","author":"Rambeck","year":"1987","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0024|jcph170-cit-0024","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0022-3476(85)80689-2","article-title":"Carbamazepine and carbamazepine-10,11-epoxide serum concentrations in epileptic children","volume":"106","author":"Furlanut","year":"1985","journal-title":"J Pediatr."},{"key":"10.1002\/jcph.170-BIB0025|jcph170-cit-0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/03602537909046437","article-title":"Action of pregnancy and various progesterones on hepatic microsomal activites","volume":"9","author":"Feuer","year":"1979","journal-title":"Drug Metab Rev."},{"key":"10.1002\/jcph.170-BIB0026|jcph170-cit-0026","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/bdd.2510130604","article-title":"Distribution of carbamazepine and its epoxide in blood compartments in adolescent and adult epileptic patients","volume":"13","author":"Bonneton","year":"1992","journal-title":"Biopharm Drug Dispos."},{"key":"10.1002\/jcph.170-BIB0027|jcph170-cit-0027","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1365-2710.2004.00557.x","article-title":"Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data","volume":"29","author":"Jiao","year":"2004","journal-title":"J Clin Pharm Ther."},{"key":"10.1002\/jcph.170-BIB0028|jcph170-cit-0028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/00007691-198609000-00012","article-title":"Carbamazepine drug interactions","volume":"8","author":"Baciewicz","year":"1986","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0029|jcph170-cit-0029","first-page":"281","article-title":"Inhibitory effect of valproic acid on the disposition of carbamazepine and carbamazepine-10,11-epoxide in the rat","volume":"14","author":"Chang","year":"1986","journal-title":"Drug Metab Dispos."},{"key":"10.1002\/jcph.170-BIB0030|jcph170-cit-0030","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2710.2011.01296.x","article-title":"Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients","volume":"37","author":"El Desoky","year":"2012","journal-title":"J Clin Pharm Ther."},{"key":"10.1002\/jcph.170-BIB0031|jcph170-cit-0031","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/00007691-198412000-00005","article-title":"Free and total plasma concentrations of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients: diurnal fluctuations and relationship with side effects","volume":"6","author":"Riva","year":"1984","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0032|jcph170-cit-0032","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1528-1157.1984.tb03446.x","article-title":"Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects","volume":"25","author":"Riva","year":"1984","journal-title":"Epilepsia."},{"key":"10.1002\/jcph.170-BIB0033|jcph170-cit-0033","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00007691-198507030-00007","article-title":"Lateral gaze nystagmus in carbamazepine-treated epileptic patients: correlation with total and free plasma concentrations of parent drug and its 10,11-epoxide metabolite","volume":"7","author":"Riva","year":"1985","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0034|jcph170-cit-0034","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/archneur.1984.04050190036011","article-title":"Interdosage fluctuations in plasma carbamazepine concentration determine intermittent side effects","volume":"41","author":"Tomson","year":"1984","journal-title":"Arch Neurol."},{"key":"10.1002\/jcph.170-BIB0035|jcph170-cit-0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/00007691-199708000-00010","article-title":"Comparison by external quality assessment of performance of analytical systems for measurement of therapeutic drugs in serum","volume":"19","author":"Tsanaclis","year":"1997","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0036|jcph170-cit-0036","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0009-9120(01)00186-2","article-title":"Characterization of cross reactivity by carbamazepine 10,11-epoxide with carbamazepine assays","volume":"34","author":"Shen","year":"2001","journal-title":"Clin Biochem."},{"key":"10.1002\/jcph.170-BIB0037|jcph170-cit-0037","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0920-1211(93)90050-H","article-title":"Steady state pharmacokinetics of conventional versus controlled-release carbamazepine in patients with epilepsy","volume":"14","author":"Bonneton","year":"1993","journal-title":"Epilepsy Res."},{"key":"10.1002\/jcph.170-BIB0038|jcph170-cit-0038","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1157.1994.tb02932.x","article-title":"Rapid reversibility of autoinduction of carbamazepine metabolism after temporary discontinuation","volume":"35","author":"Schaffler","year":"1994","journal-title":"Epilepsia."},{"key":"10.1002\/jcph.170-BIB0039|jcph170-cit-0039","unstructured":"DBS Technical Tips Whatman part of GE healthcare 2011 https:\/\/promo.gelifesciences.com\/NA\/k11286\/misc\/fta\/Practical_tips_for_dried_blood_spot_analysis.pdf)"},{"key":"10.1002\/jcph.170-BIB0040|jcph170-cit-0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/FTD.0b013e31819e91ce","article-title":"Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls","volume":"31","author":"Edelbroek","year":"2009","journal-title":"Ther Drug Monit."},{"key":"10.1002\/jcph.170-BIB0041|jcph170-cit-0041","doi-asserted-by":"crossref","first-page":"1631S","DOI":"10.1093\/jn\/131.5.1631S","article-title":"Use of filter paper for the collection and analysis of human whole blood specimens","volume":"131","author":"Mei","year":"2001","journal-title":"J Nutr."},{"key":"10.1002\/jcph.170-BIB0042|jcph170-cit-0042","doi-asserted-by":"crossref","first-page":"e57787","DOI":"10.1371\/journal.pone.0057787","article-title":"Blood and dried blood spot telomere length measurement by qPCR: assay considerations","volume":"8","author":"Zanet","year":"2013","journal-title":"PLoS ONE."},{"issue":"20","key":"10.1002\/jcph.170-BIB0043|jcph170-cit-0043","first-page":"1918","article-title":"Potential of dried blood self-sampling for cyclosporine c(2) monitoring in transplant outpatients","volume":"2010","author":"Leichtle","year":"2010","journal-title":"J Transplant."},{"key":"10.1002\/jcph.170-BIB0044|jcph170-cit-0044","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/FTD.0b013e31827d76ce","article-title":"Clinical validation of dried blood spot sampling in therapeutic drug monitoring of ciclosporin A in allogeneic stem cell transplant recipients: direct comparison between capillary and venous sampling","volume":"35","author":"Wilhelm","year":"2013","journal-title":"Ther Drug Monit."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.170","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/jcph.170\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:30:17Z","timestamp":1715941817000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.170"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2013,9,20]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.170","relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9,20]]}}}